The Incretin Effect

Definition

The incretin effect is the observation that oral glucose produces a substantially greater insulin response (50–70% greater) than an equivalent amount of glucose delivered intravenously, despite identical blood glucose levels. This amplified response is mediated by gut-derived hormones — incretins — released from intestinal cells in response to nutrient ingestion. The incretin effect accounts for approximately 50–70% of total postprandial insulin secretion in healthy individuals.

The two incretin hormones

GLP-1 (Glucagon-Like Peptide-1)

Secreted by intestinal L-cells (predominantly ileum and colon) in response to carbohydrate and fat ingestion.

Key actions:

• Glucose-dependent insulin secretion: Enhances insulin release from pancreatic beta cells only when glucose is elevated — this glucose-dependence is the safety mechanism that limits hypoglycemia risk
• Glucagon suppression: Reduces alpha cell glucagon secretion, decreasing hepatic glucose output
• Gastric emptying delay: Slows nutrient transit from stomach to small intestine, prolonging satiety and flattening postprandial glucose spikes
• Appetite suppression: Acts on hypothalamic appetite centers (arcuate nucleus, area postrema) to reduce hunger
• Beta cell preservation: Preclinical evidence suggests GLP-1 signaling promotes beta cell proliferation and inhibits apoptosis

Native GLP-1 has a half-life of approximately 2–3 minutes due to rapid degradation by dipeptidyl peptidase-4 (DPP-4). Pharmacological GLP-1 agonists are engineered to resist DPP-4 degradation, extending half-life from minutes to days (liraglutide: ~13 hours) or a full week (semaglutide: ~7 days; tirzepatide: ~5 days).

GIP (Glucose-Dependent Insulinotropic Polypeptide)

Secreted by intestinal K-cells (predominantly duodenum and jejunum) in response to glucose and fat.

Key actions:

• Glucose-dependent insulin secretion: Similar to GLP-1, enhances insulin release in a glucose-dependent manner
• Fat metabolism: GIP receptors on adipocytes regulate lipid storage and mobilization — the directionality of this effect depends on the metabolic context
• Bone metabolism: GIP signaling supports osteoblast function and bone density
• Beta cell support: Promotes beta cell survival and function

The GIP paradox: GIP was historically considered potentially obesogenic because of its role in adipocyte lipid handling. However, pharmacological GIP receptor activation (as in tirzepatide) at supraphysiological doses appears to produce different effects than physiological GIP — enhanced fat oxidation, improved insulin sensitivity, and potentially better lean mass preservation during weight loss.

The impaired incretin effect in type 2 diabetes

In type 2 diabetes, the incretin effect is severely blunted — oral glucose produces only 20–30% more insulin than intravenous glucose (compared to 50–70% in healthy individuals). This impairment is driven by:

• Reduced GLP-1 secretion: L-cell GLP-1 release is modestly reduced in T2D
• GIP resistance: Beta cell responsiveness to GIP is substantially impaired — the GIP signal is present but the response is blunted
• Beta cell dysfunction: The incretin-amplified insulin secretion pathway requires functional beta cells to translate the signal into insulin release

Restoring incretin signaling through pharmacological GLP-1 agonists partially bypasses this impairment — the supraphysiological GLP-1 levels achieved by drugs like semaglutide overwhelm the reduced sensitivity.

Pharmacological exploitation

DPP-4 inhibitors (gliptins)

Prevent the breakdown of endogenous GLP-1 and GIP, modestly increasing their circulating levels. Effect size is limited because they only protect what the gut naturally produces. Examples: sitagliptin, saxagliptin, linagliptin.

GLP-1 receptor agonists

Provide pharmacological GLP-1 signaling at levels 5–10× higher than physiological. The weight loss and metabolic effects of semaglutide come primarily from the appetite suppression and gastric emptying delay — effects that become pronounced at supraphysiological GLP-1 receptor activation.

Dual GLP-1/GIP agonists (tirzepatide)

Activate both incretin receptors simultaneously. The rationale is additive or synergistic metabolic benefit. The clinical reality (SURMOUNT trials) confirms that dual agonism produces greater weight loss and metabolic improvement than GLP-1 alone.

Triple agonists (retatrutide)

Add glucagon receptor activation to the GLP-1/GIP combination. Glucagon promotes hepatic fat mobilization, thermogenesis, and energy expenditure — effects that are not part of the traditional incretin axis but complement it for metabolic syndrome treatment.

Why the incretin effect matters beyond diabetes

The discovery that GLP-1 agonists suppress appetite through hypothalamic signaling — an effect separable from their glucose-lowering action — reframed obesity from a behavioral condition to a neurobiological one. The incretin pathway proved that gut-derived hormones directly regulate the brain's hunger circuitry, and that pharmacological modulation of this pathway produces clinically significant weight loss.

This insight — that a gut hormone pathway can be pharmacologically targeted to treat obesity — is the foundational biology behind the most important class of obesity medications ever developed.